MDACC Study No:ID02-645 ( NCT No: NCT00505921)
Title:Autologous and Allogeneic Transplantation for T-Cell Lymphoma: Impact of Campath -1H and Soluble CD52
Principal Investigator:Issa F. Khouri
Treatment Agent:Campath-1H
Study Status:Terminated
Study Description:The goal of this clinical research study is to see if high dose chemotherapy
and Campath -1H followed by a transplant of the patient’s own blood stem cells
can shrink or slow the growth of the lymphoma. The safety of this treatment
will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Blood And Marrow Transplantation
Phase of Study:Phase II
Treatment Agents:Campath-1H
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:3 to 4 weeks
Supported By:N/A
Return Visit:3 to 5 times weekly up to day 100 (if allogeneic),
Every 3 to 6 months for 2 years for all patients.
Home Care:None

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Issa F. Khouri
Dept:Stem Cell Transplantation and Cellular Therapy
For Clinical Trial Enrollment:713-745-2803
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults